Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 studyJonathan P. Piccini, Veronika Eder, Moritz Mirna et al.|The Lancet|2022Cited by 310
Clinical implications of fetuin-APeter Jirak, Hermann Salmhofer, Michael Lichtenauer et al.|Advances in clinical chemistry|2019Cited by 62
Regenerative Cardiovascular Therapies: Stem Cells and BeyondBernhard Wernly, Michael Lichtenauer, Moritz Mirna et al.|International Journal of Molecular Sciences|2019Cited by 59
Transcatheter aortic valve implantation in a patient with suspected hereditary von Willebrand disease and severe gastrointestinal bleeding – a case reportMoritz Mirna, Uta C. Hoppe, Mathias Ausserwinkler et al.|Scottish Medical Journal|2019Cited by 5